1. Acteoside relieves diabetic retinopathy through the inhibition of Müller cell reactive hyperplasia by regulating TXNIP and mediating Kir4.1 channels in a PI3K/Akt-dependent manner.
- Author
-
Xi X, Liu X, Chen Q, Ma J, Wang X, Gui Y, Zhang Y, and Li Y
- Subjects
- Animals, Rats, Male, Cell Proliferation drug effects, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental metabolism, Diabetes Mellitus, Experimental complications, Hyperplasia drug therapy, Hyperplasia metabolism, Rats, Sprague-Dawley, Cell Line, Glucose metabolism, Retina metabolism, Retina drug effects, Retina pathology, Cell Cycle Proteins, Polyphenols, Kcnj10 Channel, Diabetic Retinopathy drug therapy, Diabetic Retinopathy metabolism, Diabetic Retinopathy pathology, Ependymoglial Cells drug effects, Ependymoglial Cells metabolism, Ependymoglial Cells pathology, Proto-Oncogene Proteins c-akt metabolism, Glucosides pharmacology, Phosphatidylinositol 3-Kinases metabolism, Signal Transduction drug effects, Potassium Channels, Inwardly Rectifying metabolism, Potassium Channels, Inwardly Rectifying genetics, Carrier Proteins metabolism, Carrier Proteins genetics, Phenols pharmacology, Phenols therapeutic use
- Abstract
Diabetic retinopathy (DR) is a severe microangiopathy of diabetes. Müller cells play an important role in the development of DR. Acteoside (ACT) has been reported to be effective in the treatment of DR. In this study, we explored the molecular mechanism of ACT in the treatment of DR from the perspective of the reactive proliferation of Müller cells. The effect of ACT on DR was investigated via high-glucose (HG) treatment of Müller RMC-1 cells and an injection of streptozotocin (STZ) in constructed DR cells and animal models. The results showed that after ACT treatment, damage to the retinal structure in DR rats was alleviated, the number of hemangiomas was reduced, and the penetration of blood vessels was weakened. In addition, ACT treatment improved the hypertrophy and gliogenesis of Müller cells during DR, promoted the expression of Kir4.1 and activated the PI3K/Akt signaling pathway. ACT treatment inhibited the proliferation and migration of RMC-1 cells and promoted the expression of Kir4.1. TXNIP overexpression effectively reversed the inhibitory effect of ACT on the proliferation and migration of Müller cells and its induction of Kir4.1 expression. In addition, TXNIP knockdown effectively reversed the inhibitory effect of HG on the expression of p-PI3K and p-Akt, whereas TXNIP overexpression had the opposite effect, and treatment with the PI3K/AKT pathway inhibitor LY294002 effectively reversed the effect of TXNIP knockdown. Animal experiments also confirmed that the therapeutic effect of ACT on DR rats could be reversed by the overexpression of TXNIP or LY294002. In conclusion, ACT inhibits Müller cell reactive proliferation and alleviates diabetic retinopathy by regulating TXNIP and mediating the expression of Kir4.1 channels in a PI3K/Akt-dependent manner., Competing Interests: The authors declare that they have no competing interests., (Copyright: © 2024 Xi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF